Nivestim
Hodgkin'S Lymphoma, Lymphocytic Depletion
National Cancer Institute (NCI)protein_peptidePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Hodgkin'S Lymphoma, Lymphocytic Depletion cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etoposide Northwestern University | Phase 3 | BB |
Adriamycin National Cancer Institute (NCI) | Phase 3 | BB |
Prednisone National Cancer Institute (NCI) | Phase 3 | BB |
Isocyclophosphamide Northwestern University | Phase 3 | BB |
Cyclophosphamide Northwestern University | Phase 3 | BB |
View all 21 →
Same molecule, other indications
Nivestim is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →